# A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease

> **NCT00838396** · PHASE2 · COMPLETED · sponsor: **Indivior Inc.** · enrollment: 58 (actual)

## Conditions studied

- GERD

## Interventions

- **DRUG:** XP19986 CR
- **DRUG:** Placebo for XP19986 CR

## Key facts

- **NCT ID:** NCT00838396
- **Lead sponsor:** Indivior Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2016-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00838396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00838396, "A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00838396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*